On this page
Triamcinolone Acetonide
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Triamcinolone Acetonide | 1 mg/g | 1014314 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 205592-001 | TRIAMCINOLONE ACETONIDE | PASTE | TRIAMCINOLONE ACETONIDE | Prescription | AT |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | January 12, 2017 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250915). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Triamcinolone Acetonide Dental Paste USP, 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Press a small dab (about 1/4 inch) to the lesion until a thin film develops. A larger quantity may be required for coverage of some lesions. For optimal results use only enough to coat the lesion with a thin film. Do not rub in. Attempting to spread this preparation may result in granular, gritty sensation and cause it to crumble. After application, however, a smooth, slippery film develops. The preparation should be applied at bedtime to permit steroid contact with the lesion throughout the night. Depending on the severity of symptoms, it may be necessary to apply the preparation two or three times a day, preferably after meals. If significant repair or regeneration has not occurred in seven days, further investigation is advisable.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Triamcinolone Acetonide Dental Paste USP, 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS The following local adverse reactions may occur with corticosteroid-containing dental pastes: burning, itching, irritation, dryness, blistering or peeling not present prior to therapy, perioral dermatitis, allergic contact dermatitis, maceration of the oral mucosa, secondary infection, and atrophy of the oral mucosa. Also, see PRECAUTIONS for potential effects of systemic absorption. To report SUSPECTED ADVERSE REACTINS, contact Sun Pharmaceutical Industries, Inc., at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Triamcinolone Acetonide Dental Paste USP, 0.1%, contains the corticosteroid triamcinolone acetonide in an adhesive vehicle suitable for application to oral tissues. Triamcinolone acetonide is designated chemically as 9-fluoro-11β, 16α, 17, 21-tetrahydroxypregna-1, 4-diene-3, 20-dione cyclic 16, 17-acetal with acetone. The structural formula of triamcinolone acetonide is as follows: C 24 H 31 FO 6 MW 434.50 Each gram of triamcinolone acetonide dental paste contains 1 mg triamcinolone acetonide in an emollient dental paste containing carboxymethylcellulose sodium, gelatin, and pectin in a plasticized hydrocarbon gel (a polyethylene and mineral oil gel base). Chemical Structure
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Triamcinolone Acetonide Dental Paste USP, 0.1% is supplied as light beige odorless paste with fine gritty texture, having no lumps filled in aluminum or laminated tubes containing 5 g of dental paste in laminated tubes (NDC 70752-140-16) and 5 g of dental paste in aluminum tubes (NDC 70752-140-17). Storage Keep tightly closed. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: TRIAMCINOLONE ACETONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 72162-2318-2 | 72162-2318 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-2318-2) / 5 g in 1 TUBE | May 20, 2024 |
| 0713-0655-40 | 0713-0655 | Cosette Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (0713-0655-40) / 5 g in 1 TUBE | January 13, 2017 |
| 68788-7814-5 | 68788-7814 | Preferred Pharmaceuticals Inc | 1 TUBE in 1 CARTON (68788-7814-5) / 5 g in 1 TUBE | November 3, 2020 |
| 68788-8841-5 | 68788-8841 | Preferred Pharmaceuticals Inc. | 1 TUBE in 1 CARTON (68788-8841-5) / 5 g in 1 TUBE | March 20, 2025 |
| 68788-8386-5 | 68788-8386 | Preferred Pharmaceuticals, Inc. | 1 TUBE in 1 CARTON (68788-8386-5) / 5 g in 1 TUBE | March 1, 2023 |
| 70752-140-16 | 70752-140 | QUAGEN PHARMACEUTICALS LLC | 1 TUBE in 1 CARTON (70752-140-16) / 5 g in 1 TUBE | January 15, 2023 |
| 70752-140-17 | 70752-140 | QUAGEN PHARMACEUTICALS LLC | 1 TUBE in 1 CARTON (70752-140-17) / 5 g in 1 TUBE | January 15, 2023 |
| 64980-320-05 | 64980-320 | Rising Pharma Holdings, Inc. | 48 CARTON in 1 BOX (64980-320-05) / 1 TUBE in 1 CARTON / 5 g in 1 TUBE | July 7, 2010 |
| 51672-1267-5 | 51672-1267 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1267-5) / 5 g in 1 TUBE | October 1, 1986 |
| 51672-1267-8 | 51672-1267 | Sun Pharmaceutical Industries, Inc. | 1 TUBE in 1 CARTON (51672-1267-8) / 7.5 g in 1 TUBE | October 1, 1986 |
| 72162-2318 | 72162-2318 | Bryant Ranch Prepack | — | January 15, 2023 |
| 0713-0655 | 0713-0655 | Cosette Pharmaceuticals, Inc. | — | January 13, 2017 |
| 68788-7814 | 68788-7814 | Preferred Pharmaceuticals Inc | — | November 3, 2020 |
| 68788-8841 | 68788-8841 | Preferred Pharmaceuticals Inc. | — | March 20, 2025 |
| 68788-8386 | 68788-8386 | Preferred Pharmaceuticals, Inc. | — | March 1, 2023 |
| 70752-140 | 70752-140 | QUAGEN PHARMACEUTICALS LLC | — | January 15, 2023 |
| 64980-320 | 64980-320 | Rising Pharma Holdings, Inc. | — | July 7, 2010 |
| 51672-1267 | 51672-1267 | Sun Pharmaceutical Industries, Inc. | — | October 1, 1986 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.